Skip to main content

Table 2 Results of univariate LogRank analyses of clinical and molecular variables

From: CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients

Criteria Status n [%] PFS [month] OS [month]
Median 95% CI LogRank Median 95% CI LogRank
FIGO I/II 19 10.4 Not reached   p < 0.001 145 46.0–244.0 p = 0.013
III/IV 163 89.6 29 25.5–32.5 62 49.4–74.6
Resection R0 139 76.8 38 28.3–47.8 p < 0.001 78 71.2–84.8 p < 0.001
R1/2 42 23.2 20 13.9–26.1 49 41.2–56.8
Histology Serous 154 82.8 30 26.6–33.4 p = 0.075 78 34.9–121.1 p = 0.581
Non-serous 32 17.2 58 0–121.1 64 54.7–73.3
Methylation No marker 77 41.4 30 14.8–45.2 p = 0.147 78 52.5–103.6 p = 0.195
 ≥ 1 marker 109 58.6 31 27.4–34.7 62 50.1–73.9
CAMK2N1 U 170 91.4 31 25.2–36.8 p = 0.021 74 62.3–85.2 p = 0.06
M 16 8.6 16 9.3–22.8 47 31.2–62.8
ATL1 U 159 85.5 31 25.2–36.8 p = 0.179 64 52.9–75.1 p = 0.273
M 27 14.5 27 20.2–33.8 65 26.6–103.4
KATNAL2 U 111 59.7 33 23.3–42.1 p = 0.125 78 55.7–100.3 p = 0.161
M 75 40.3 29 24.6–33.5 59 52.6–65.4
KRT86 U 143 76.9 33 25.1–40.9 p = 0.001 64 50.1–77.9 p = 0.290
M 43 23.1 26 18.1–33.1 73 54.4–91.6
RUNX3 U 160 86.0 31 26.9–35.1 p = 0.126 73 62.3–83.7 p = 0.179
M 26 14.0 21 4.7–37.2 55 33.0–77
CAMK2N1/RUNX3 U 152 81.7 32 26.0–38.0 p = 0.032 74 61.7–86.3 p = 0.045
M 34 18.3 21 3.8–38.1 57 43.6–70.4
CAMK2N1/KRT86 U 133 71.5 37 25.9–48.1 p < 0.001 74 58.0–90.0 p = 0.128
M 53 28.5 26 18.5–32.8 60 42.9–77.1
CAMK2N1/KRT86/RUNX3 U 123 66.1 37 19.2–54.8 p = 0.001 74 57.0–91.0 p = 0.106
M 63 33.9 29 23.0–35.0 60 43.1–76.9
BRCA1 U 166 89.7 31 27.2–34.8 p = 0.626 73 61.4–84.6 p = 0.308
M 19 10.3 25 11.8–37.4 57 43.8–70.2
  1. LogRank results with significance are marked in bold. U, unmethylated; M, methylated. Marker combinations are positive (methylated) if at least one single marker is methylated (<OR> combinations) otherwise the combination is scored as unmethylated